Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Templates to Screen Targets for ImClone

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular Templates, a Georgetown, Texas-based firm that has developed a targeted biologics platform, said that it has signed an agreement to screen potential drug targets for ImClone Systems, a wholly-owned subsidiary of Eli Lilly.

Under terms of the pact, Molecular Templates will identify Engineered Toxin Bodies — a new class of small biologic therapeutics derived from modified bacterial toxins — against undisclosed oncology targets of interest selected by ImClone. Molecular Templates uses its Direct Select Platform to create ETB libraries that can be screened in high throughput to identify therapeutic targets and molecules for various disease states, it said.

ImClone will conduct preclinical studies using the ETBs, evaluating their therapeutic potential in oncology. Following the evaluation period, the firms have an option to continue exclusive development of selected ETBs by ImClone, which would potentially be commercialized by Eli Lilly.

Molecular Templates will receive upfront, milestone, and royalty payments if any ETBs are selected for further development and commercialization. Financial and other terms were not disclosed.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.